THIS MATERIAL IS A MARKETING COMMUNICATION.
China’s Clinical Research Services Industry
The Pharmaceutical R&D Process
The process involves the discovery of drug candidates and the subsequent testing of drug candidates to demonstrate their safety and efficacy in order to obtain regulatory approval and enter the market. The process is generally costly, complex, risky and time-consuming. The entire process generally consists of four stages, namely (i) discovery, (ii) pre-clinical, (iii) clinical and registration including phases I to IV clinical trials and (iv) manufacturing.
R&D Outsourcing Services
The complex, risky, time-consuming and expensive nature of the pharmaceutical R&D process creates significant demand for pharmaceutical R&D outsourcing services. Such services are provided by two types of pharmaceutical R&D outsourcing service providers, namely CROs (Contract Research Organization) and CDMOs (Contract Development Manufacturing Organization). CROs support pharmaceutical companies with various R&D services covering the discovery, pre-clinical, as well as clinical and registration stages, while CDMOs mainly engage in CMC (Chemistry, Manufacturing and Controls) services in the manufacturing stage.
With the continuous development of the pharmaceutical industry, CROs are playing an increasingly important role in the capital-intensive, complicated, risky and time-consuming pharmaceutical R&D process. CROs provide comprehensive R&D solutions covering (i) discovery stage, (ii) pre-clinical stage and (iii) clinical stage including phase I to IV clinical trials.
Pharmaceutical companies rely on CROs with strong project management and scientific expertise, a specialized and experienced talent pool, innovative technologies and extensive regulatory experience to manage complex projects to reduce R&D risks and costs, and accelerate the development of safe and effective drugs.
The key factors that are driving growth in global as well as China’s pharmaceutical R&D services market include:
- Rising R&D expenditure, driving the growth for CROs.
- Increasing complexity of R&D process - this has led many pharmaceutical companies to outsource more R&D activities to experienced CROs with advanced technology.
- Cost savings - Amid the increased competition for new drug development and lower R&D yield, CROs help them efficiently and expertly manage R&D activities while reducing costs and risks.
- Emerging biotech companies - Numerous biotech companies have emerged, especially in China. Due to limited in-house resources and capabilities, many of these emerging biotech companies rely extensively on third-party service providers to navigate their complex R&D projects, generating additional demands for CRO services.
- Favorable government policies in China – The Chinese government has undertaken a reform of its regulatory review and approval system that covers the entire value chain of China’s pharmaceutical market, from clinical trials, regulatory submission, manufacturing to medical insurance coverage. The reform has led to more business opportunities for CROs specialized in innovative drug development. As part of the reform, China has issued a variety of favorable government policies to encourage the development of the pharmaceutical CRO market, such as the 13th Five-Year Plan for International Outsourcing Service Industry Development published in 2017.
Market Sizing by Geographies
The US is the largest clinical CRO market at US$20.9 bln in 2019, and it is expected to grow at 8% compound annual growth rate (CAGR) during 2019-24. While China’s clinical CRO market is in relatively early stage, it is expected to grow rapidly from US$3.7 bln in 2019 to US$13.7 bln in 2024, a CAGR of 30%.
In China, the number of clinical trials increased from 339 in 2015 to 1,031 in 2019. As pharmaceutical R&D continues to globalize and China becomes an integral part of the global pharmaceutical R&D industry, the number of multi-regional clinical trials (MRCTs) conducted in China has also increased. Since China joined the ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) in 2017, an organization that aims to unify technical and regulatory requirements of different countries for pharmaceuticals development and registration, China has been updating and conforming to its regulations governing the clinical development of pharmaceuticals to those of the developed markets. In particular, clinical data generated overseas can be used as supplementary data to support registration applications in China. On the other hand, there is a growing trend for multinational pharmaceutical companies to conduct MRCTs with clinical sites in China to support their registration application to NMPA (National Medical Products Administration, formerly known as China Food and Drug Administration).
Staying Ahead with Mirae Asset’s Latest Insights
Disclaimer & Information for Investors
No distribution, solicitation or advice: This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service.
The views and information discussed or referred in this document are as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. In addition, the opinions expressed may differ from those of other Mirae Asset Global Investments’ investment professionals.
Investment involves risk: Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Sources: Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (“MAGI”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGI as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Information for EU investors pursuant to Regulation (EU) 2019/1156: This document is a marketing communication and is intended for Professional Investors only. A Prospectus is available for the Mirae Asset Global Discovery Fund (the “Company”) a société d'investissement à capital variable (SICAV) domiciled in Luxembourg structured as an umbrella with a number of sub-funds. Key Investor Information Documents (“KIIDs”) are available for each share class of each of the sub-funds of the Company.
The Company’s Prospectus and the KIIDs can be obtained from www.am.miraeasset.eu/fund-literature/ . The Prospectus is available in English, French, German, and Danish, while the KIIDs are available in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the “UCITS Directive”). Please refer to the Prospectus and the KIID before making any final investment decisions.
A summary of investor rights is available in English from www.am.miraeasset.eu/investor-rights-summary/.
The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. FundRock Management Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.
Hong Kong: This document is intended for Hong Kong investors. Before making any investment decision to invest in the Fund, Investors should read the Fund’s Prospectus and the information for Hong Kong investors (of applicable) of the Fund for details and the risk factors. The individual and Mirae Asset Global Investments (Hong Kong) Limited may hold the individual securities mentioned. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Copyright 2023. All rights reserved. No part of this document may be reproduced in any form, or referred to in any other publication, without express written permission of Mirae Asset Global Investments (Hong Kong) Limited.